Adaptive Behavior in Young Autistic Children: Associations with Irritability and ADHD Symptoms / Naomi O. DAVIS ; Marina SPANOS ; Maura SABATOS-DEVITO ; Rachel AIELLO ; Grace T. BARANEK ; Scott N. COMPTON ; Helen L. EGGER ; Lauren FRANZ ; Soo-Jeong KIM ; Bryan H. KING ; Alexander KOLEVZON ; Christopher J. MCDOUGLE ; Kevin SANDERS ; Jeremy VEENSTRA-VANDERWEELE ; Linmarie SIKICH ; Scott H. KOLLINS ; Geraldine DAWSON in Journal of Autism and Developmental Disorders, 54-9 (September 2024)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 54-9 (September 2024) . - p.3559-3566 Titre : Adaptive Behavior in Young Autistic Children: Associations with Irritability and ADHD Symptoms Type de document : Texte imprimé et/ou numérique Auteurs : Naomi O. DAVIS, Auteur ; Marina SPANOS, Auteur ; Maura SABATOS-DEVITO, Auteur ; Rachel AIELLO, Auteur ; Grace T. BARANEK, Auteur ; Scott N. COMPTON, Auteur ; Helen L. EGGER, Auteur ; Lauren FRANZ, Auteur ; Soo-Jeong KIM, Auteur ; Bryan H. KING, Auteur ; Alexander KOLEVZON, Auteur ; Christopher J. MCDOUGLE, Auteur ; Kevin SANDERS, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur ; Linmarie SIKICH, Auteur ; Scott H. KOLLINS, Auteur ; Geraldine DAWSON, Auteur Article en page(s) : p.3559-3566 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Attention-deficit/hyperactivity disorder (ADHD) symptoms affect 40-60% of autistic children and have been linked to differences in adaptive behavior. It is unclear whether adaptive behavior in autistic youth is directly impacted by co-occurring ADHD symptoms or by another associated feature of both autism and ADHD, such as increased irritability. The current study examined relationships between irritability, ADHD symptoms, and adaptive behavior in 3- to 7-year-old autistic children. Results suggest that, after adjusting for co-occurring ADHD symptoms, higher levels of irritability are associated with differences in social adaptive behavior specifically. Understanding relationships between irritability, ADHD, and adaptive behavior in autistic children is critical because measures of adaptive behavior, such as the Vineland Scales of Adaptive Functioning, are often used as a proxy for global functioning, as well as for developing intervention plans and measuring outcomes as primary endpoints in clinical trials. En ligne : https://doi.org/10.1007/s10803-022-05753-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=534 [article] Adaptive Behavior in Young Autistic Children: Associations with Irritability and ADHD Symptoms [Texte imprimé et/ou numérique] / Naomi O. DAVIS, Auteur ; Marina SPANOS, Auteur ; Maura SABATOS-DEVITO, Auteur ; Rachel AIELLO, Auteur ; Grace T. BARANEK, Auteur ; Scott N. COMPTON, Auteur ; Helen L. EGGER, Auteur ; Lauren FRANZ, Auteur ; Soo-Jeong KIM, Auteur ; Bryan H. KING, Auteur ; Alexander KOLEVZON, Auteur ; Christopher J. MCDOUGLE, Auteur ; Kevin SANDERS, Auteur ; Jeremy VEENSTRA-VANDERWEELE, Auteur ; Linmarie SIKICH, Auteur ; Scott H. KOLLINS, Auteur ; Geraldine DAWSON, Auteur . - p.3559-3566. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 54-9 (September 2024) . - p.3559-3566 Index. décimale : PER Périodiques Résumé : Attention-deficit/hyperactivity disorder (ADHD) symptoms affect 40-60% of autistic children and have been linked to differences in adaptive behavior. It is unclear whether adaptive behavior in autistic youth is directly impacted by co-occurring ADHD symptoms or by another associated feature of both autism and ADHD, such as increased irritability. The current study examined relationships between irritability, ADHD symptoms, and adaptive behavior in 3- to 7-year-old autistic children. Results suggest that, after adjusting for co-occurring ADHD symptoms, higher levels of irritability are associated with differences in social adaptive behavior specifically. Understanding relationships between irritability, ADHD, and adaptive behavior in autistic children is critical because measures of adaptive behavior, such as the Vineland Scales of Adaptive Functioning, are often used as a proxy for global functioning, as well as for developing intervention plans and measuring outcomes as primary endpoints in clinical trials. En ligne : https://doi.org/10.1007/s10803-022-05753-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=534

Anxiety symptom trajectories from treatment to 5- to 12-year follow-up across childhood and adolescence / Sunhye BAI in Journal of Child Psychology and Psychiatry, 64-9 (September 2023)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 64-9 (September 2023) . - p.1336-1345 Titre : Anxiety symptom trajectories from treatment to 5- to 12-year follow-up across childhood and adolescence Type de document : Texte imprimé et/ou numérique Auteurs : Sunhye BAI, Auteur ; Benjamin ROLON-ARROYO, Auteur ; John T. WALKUP, Auteur ; Philip C. KENDALL, Auteur ; Golda S. GINSBURG, Auteur ; Courtney P. KEETON, Auteur ; Anne Marie ALBANO, Auteur ; Scott N. COMPTON, Auteur ; Dara SAKOLSKY, Auteur ; John PIACENTINI, Auteur ; Tara S. PERIS, Auteur Article en page(s) : p.1336-1345 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Objective The current study examined trajectories of anxiety during (a) acute treatment and (b) extended follow-up to better characterize the long-term symptom trajectories of youth who received evidence-based intervention for anxiety disorders using a person-centered approach. Method Participants were 319 youth (age 7-17?years at enrollment), who participated in a multicenter randomized controlled trial for the treatment of pediatric anxiety disorders, Child/Adolescent Anxiety Multimodal Study, and a 4-year naturalistic follow-up, Child/Adolescent Anxiety Multimodal Extended Long-term Study, an average of 6.5?years later. Using growth mixture modeling, the study identified distinct trajectories of anxiety across acute treatment (Weeks 0-12), posttreatment (Weeks 12-36), and the 4-year-long follow-up, and identified baseline predictors of these trajectories. Results Three nonlinear anxiety trajectories emerged: "short-term responders" who showed rapid treatment response but had higher levels of anxiety during the extended follow-up; "durable responders" who sustained treatment gains; and "delayed remitters" who did not show an initial response to treatment, but showed low levels of anxiety during the maintenance and extended follow-up periods. Worse anxiety severity and better family functioning at baseline predicted membership in the delayed remitters group. Caregiver strain differentiated short-term responders from durable responders. Conclusions Findings suggest that initial response to treatment does not guarantee sustained treatment gains over time for some youth. Future follow-up studies that track treated youth across key developmental transitions and in the context of changing social environments are needed to inform best practices for the long-term management of anxiety. En ligne : https://doi.org/10.1111/jcpp.13796 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=512 [article] Anxiety symptom trajectories from treatment to 5- to 12-year follow-up across childhood and adolescence [Texte imprimé et/ou numérique] / Sunhye BAI, Auteur ; Benjamin ROLON-ARROYO, Auteur ; John T. WALKUP, Auteur ; Philip C. KENDALL, Auteur ; Golda S. GINSBURG, Auteur ; Courtney P. KEETON, Auteur ; Anne Marie ALBANO, Auteur ; Scott N. COMPTON, Auteur ; Dara SAKOLSKY, Auteur ; John PIACENTINI, Auteur ; Tara S. PERIS, Auteur . - p.1336-1345. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 64-9 (September 2023) . - p.1336-1345 Index. décimale : PER Périodiques Résumé : Objective The current study examined trajectories of anxiety during (a) acute treatment and (b) extended follow-up to better characterize the long-term symptom trajectories of youth who received evidence-based intervention for anxiety disorders using a person-centered approach. Method Participants were 319 youth (age 7-17?years at enrollment), who participated in a multicenter randomized controlled trial for the treatment of pediatric anxiety disorders, Child/Adolescent Anxiety Multimodal Study, and a 4-year naturalistic follow-up, Child/Adolescent Anxiety Multimodal Extended Long-term Study, an average of 6.5?years later. Using growth mixture modeling, the study identified distinct trajectories of anxiety across acute treatment (Weeks 0-12), posttreatment (Weeks 12-36), and the 4-year-long follow-up, and identified baseline predictors of these trajectories. Results Three nonlinear anxiety trajectories emerged: "short-term responders" who showed rapid treatment response but had higher levels of anxiety during the extended follow-up; "durable responders" who sustained treatment gains; and "delayed remitters" who did not show an initial response to treatment, but showed low levels of anxiety during the maintenance and extended follow-up periods. Worse anxiety severity and better family functioning at baseline predicted membership in the delayed remitters group. Caregiver strain differentiated short-term responders from durable responders. Conclusions Findings suggest that initial response to treatment does not guarantee sustained treatment gains over time for some youth. Future follow-up studies that track treated youth across key developmental transitions and in the context of changing social environments are needed to inform best practices for the long-term management of anxiety. En ligne : https://doi.org/10.1111/jcpp.13796 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=512

Substance use outcomes from the Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS) / Thomas M. OLINO ; Anne Marie ALBANO ; Courtney P. KEETON ; Dara SAKOLSKY ; Boris BIRMAHER ; John PIACENTINI ; Tara S. PERIS ; Scott N. COMPTON ; Elizabeth GOSCH ; Golda S. GINSBURG ; Elizabeth L. PINNEY ; Philip C. KENDALL in Journal of Child Psychology and Psychiatry, 65-7 (July 2024)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 65-7 (July 2024) . - p.910-920 Titre : Substance use outcomes from the Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS) Type de document : Texte imprimé et/ou numérique Auteurs : Thomas M. OLINO, Auteur ; Anne Marie ALBANO, Auteur ; Courtney P. KEETON, Auteur ; Dara SAKOLSKY, Auteur ; Boris BIRMAHER, Auteur ; John PIACENTINI, Auteur ; Tara S. PERIS, Auteur ; Scott N. COMPTON, Auteur ; Elizabeth GOSCH, Auteur ; Golda S. GINSBURG, Auteur ; Elizabeth L. PINNEY, Auteur ; Philip C. KENDALL, Auteur Article en page(s) : p.910-920 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Background Substance use problems and anxiety disorders are both highly prevalent and frequently cooccur in youth. The present study examined the benefits of successful anxiety treatment at 3-12?years after treatment completion on substance use outcomes (i.e. diagnoses and lifetime expected use). Methods The sample was from the Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS), a naturalistic follow-up study to the Child/Adolescent Anxiety Multimodal Study (CAMS) which randomized youth to cognitive behavioral therapy (CBT; Coping cat), medication (sertraline), their combination, or pill placebo. The first CAMELS visit occurred an average of 6.5?years following CAMS randomization. Participants were 319 youth (65.4% of the CAMS sample), aged 7-17?years at CAMS baseline assessment with a mean age of 17.6?years (range: 11-26?years) at the time of the first CAMELS follow-up. Substance use outcomes included diagnoses as well as lifetime substance use (i.e. alcohol and tobacco use). Results Eleven of 319 (3.4%) CAMELS participants were diagnosed with a substance use disorder at the initial follow-up visit. When compared to the population lifetime rate of 11.4%, the rate of diagnoses in the posttreated sample was significantly lower. Additionally, rates of lifetime alcohol use were lower than population rates at the initial and final follow-up visits. Rates of lifetime tobacco use were similarly lower than lifetime population rates at the initial visit (driven by significantly lower rates in the CBT treatment condition), but higher by the final visit. Furthermore, treatment remission (but not treatment response) was associated with a lower rate of substance use diagnoses at the initial follow-up visit, although rates of lifetime alcohol and tobacco use did not differ by treatment outcome. Conclusions Anxiety treatments confer a beneficial impact on problematic substance use (i.e. diagnoses) as well as on expected substance use (i.e. alcohol and tobacco use) for on average, a period of 6.5?years. En ligne : https://doi.org/10.1111/jcpp.13926 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=532 [article] Substance use outcomes from the Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS) [Texte imprimé et/ou numérique] / Thomas M. OLINO, Auteur ; Anne Marie ALBANO, Auteur ; Courtney P. KEETON, Auteur ; Dara SAKOLSKY, Auteur ; Boris BIRMAHER, Auteur ; John PIACENTINI, Auteur ; Tara S. PERIS, Auteur ; Scott N. COMPTON, Auteur ; Elizabeth GOSCH, Auteur ; Golda S. GINSBURG, Auteur ; Elizabeth L. PINNEY, Auteur ; Philip C. KENDALL, Auteur . - p.910-920. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 65-7 (July 2024) . - p.910-920 Index. décimale : PER Périodiques Résumé : Background Substance use problems and anxiety disorders are both highly prevalent and frequently cooccur in youth. The present study examined the benefits of successful anxiety treatment at 3-12?years after treatment completion on substance use outcomes (i.e. diagnoses and lifetime expected use). Methods The sample was from the Child/Adolescent Anxiety Multimodal Extended Long-term Study (CAMELS), a naturalistic follow-up study to the Child/Adolescent Anxiety Multimodal Study (CAMS) which randomized youth to cognitive behavioral therapy (CBT; Coping cat), medication (sertraline), their combination, or pill placebo. The first CAMELS visit occurred an average of 6.5?years following CAMS randomization. Participants were 319 youth (65.4% of the CAMS sample), aged 7-17?years at CAMS baseline assessment with a mean age of 17.6?years (range: 11-26?years) at the time of the first CAMELS follow-up. Substance use outcomes included diagnoses as well as lifetime substance use (i.e. alcohol and tobacco use). Results Eleven of 319 (3.4%) CAMELS participants were diagnosed with a substance use disorder at the initial follow-up visit. When compared to the population lifetime rate of 11.4%, the rate of diagnoses in the posttreated sample was significantly lower. Additionally, rates of lifetime alcohol use were lower than population rates at the initial and final follow-up visits. Rates of lifetime tobacco use were similarly lower than lifetime population rates at the initial visit (driven by significantly lower rates in the CBT treatment condition), but higher by the final visit. Furthermore, treatment remission (but not treatment response) was associated with a lower rate of substance use diagnoses at the initial follow-up visit, although rates of lifetime alcohol and tobacco use did not differ by treatment outcome. Conclusions Anxiety treatments confer a beneficial impact on problematic substance use (i.e. diagnoses) as well as on expected substance use (i.e. alcohol and tobacco use) for on average, a period of 6.5?years. En ligne : https://doi.org/10.1111/jcpp.13926 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=532

Symptom-specific effects of cognitive-behavioral therapy, sertraline, and their combination in a large randomized controlled trial of pediatric anxiety disorders / Matti CERVIN in Journal of Child Psychology and Psychiatry, 61-4 (April 2020)  

Public ISBD [article]  inJournal of Child Psychology and Psychiatry > 61-4 (April 2020) . - p.492-502 Titre : Symptom-specific effects of cognitive-behavioral therapy, sertraline, and their combination in a large randomized controlled trial of pediatric anxiety disorders Type de document : Texte imprimé et/ou numérique Auteurs : Matti CERVIN, Auteur ; Eric A. STORCH, Auteur ; John PIACENTINI, Auteur ; Boris BIRMAHER, Auteur ; Scott N. COMPTON, Auteur ; Anne Marie ALBANO, Auteur ; Elizabeth GOSCH, Auteur ; John T. WALKUP, Auteur ; Philip C. KENDALL, Auteur Article en page(s) : p.492-502 Langues : Anglais (eng) Mots-clés : CBT/cognitive behavior therapy  anxiety/anxiety disorders  child/adolescent  clinical trials  pharmacotherapy Index. décimale : PER Périodiques Résumé : BACKGROUND: Pediatric anxiety disorders are highly prevalent and associated with significant functional disabilities and lifelong morbidity. Cognitive-behavioral therapy (CBT), sertraline, and their combination are effective treatments, but little is known about how these treatments exert their effects. METHODS: Using network intervention analysis (NIA), we analyzed data from the largest randomized controlled treatment trial of pediatric anxiety disorders (Child/Adolescent Anxiety Multimodal Study, NCT00052078, clinicaltrials.gov/ct2/show/NCT00052078) and outlined the causal symptom domain-specific effects of CBT, sertraline, and their combination over the course of the 12-week treatment while taking into account both specificity and overlap between symptom domains. RESULTS: All active treatments produced positive effects with the most pronounced and consistent effects emerging in relation to psychological distress, family interference, and avoidance. Psychological distress was consistently the most and physical symptoms the least central symptom domain in the disorder network. CONCLUSIONS: All active treatments showed beneficial effects when compared to placebo, and NIA identified that these effects were exerted similarly across treatments and primarily through a reduction of psychological distress, family interference, and avoidance. CBT and sertraline may have differential mechanisms of action in relation to psychological distress. Given the lack of causal effects on interference outside family and physical symptoms, interventions tailored to target these domains may aid in the building of more effective treatments. Psychological distress and avoidance should remain key treatment focuses because of their central roles in the disorder network. The findings inform and promote developing more effective interventions. En ligne : http://dx.doi.org/10.1111/jcpp.13124 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421 [article] Symptom-specific effects of cognitive-behavioral therapy, sertraline, and their combination in a large randomized controlled trial of pediatric anxiety disorders [Texte imprimé et/ou numérique] / Matti CERVIN, Auteur ; Eric A. STORCH, Auteur ; John PIACENTINI, Auteur ; Boris BIRMAHER, Auteur ; Scott N. COMPTON, Auteur ; Anne Marie ALBANO, Auteur ; Elizabeth GOSCH, Auteur ; John T. WALKUP, Auteur ; Philip C. KENDALL, Auteur . - p.492-502. Langues : Anglais (eng) in Journal of Child Psychology and Psychiatry > 61-4 (April 2020) . - p.492-502 Mots-clés : CBT/cognitive behavior therapy  anxiety/anxiety disorders  child/adolescent  clinical trials  pharmacotherapy Index. décimale : PER Périodiques Résumé : BACKGROUND: Pediatric anxiety disorders are highly prevalent and associated with significant functional disabilities and lifelong morbidity. Cognitive-behavioral therapy (CBT), sertraline, and their combination are effective treatments, but little is known about how these treatments exert their effects. METHODS: Using network intervention analysis (NIA), we analyzed data from the largest randomized controlled treatment trial of pediatric anxiety disorders (Child/Adolescent Anxiety Multimodal Study, NCT00052078, clinicaltrials.gov/ct2/show/NCT00052078) and outlined the causal symptom domain-specific effects of CBT, sertraline, and their combination over the course of the 12-week treatment while taking into account both specificity and overlap between symptom domains. RESULTS: All active treatments produced positive effects with the most pronounced and consistent effects emerging in relation to psychological distress, family interference, and avoidance. Psychological distress was consistently the most and physical symptoms the least central symptom domain in the disorder network. CONCLUSIONS: All active treatments showed beneficial effects when compared to placebo, and NIA identified that these effects were exerted similarly across treatments and primarily through a reduction of psychological distress, family interference, and avoidance. CBT and sertraline may have differential mechanisms of action in relation to psychological distress. Given the lack of causal effects on interference outside family and physical symptoms, interventions tailored to target these domains may aid in the building of more effective treatments. Psychological distress and avoidance should remain key treatment focuses because of their central roles in the disorder network. The findings inform and promote developing more effective interventions. En ligne : http://dx.doi.org/10.1111/jcpp.13124 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=421

---

1 (1 - 4 / 4)